Ciara Kennedy, Amplyx CEO

Am­plyx touts up­beat read­out from a small PhII study for lead an­ti­fun­gal

Am­plyx, a biotech fo­cused on treat­ing pa­tients with com­pro­mised im­mune sys­tems, is tout­ing its lead pro­gram fol­low­ing a Phase II study.

The San Diego-based com­pa­ny an­nounced its re­sults Mon­day morn­ing for fos­man­ogepix, an an­ti­fun­gal that treats life-threat­en­ing Can­di­da in­fec­tions. Ex­ecs at the com­pa­ny say that topline da­ta from the study in­di­cat­ed a treat­ment suc­cess rate of 80 per­cent, meet­ing the pri­ma­ry end­point and paving the way to a piv­otal tri­al ahead.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.